More than half of the people living with ANCA-associated vasculitis (AAV) have infections caused by bacteria, fungi, or viruses,…
Articles by Margarida Maia, PhD
Q32 Bio is delaying the start of a planned Phase 2 clinical trial designed to test its ADX-097 therapy…
Being frail, that is, more vulnerable to health stressors as a result of aging-related biological changes, may put older adults…
People with ANCA-associated vasculitis (AAV) who carry certain variants in SERPINA1 — a gene that’s been previously linked to…
Low blood levels of glial fibrillary acidic protein (GFAP) are linked to more active disease and a higher risk of…
Combination maintenance therapy with Nucala (mepolizumab) and azathioprine may be more effective than either treatment alone at maintaining disease…
Tavneos (avacopan) effectively induces disease remission in adults with ANCA-associated vasculitis (AAV) and diffuse alveolar hemorrhage (DAH), that…
Nearly one year of treatment with rituximab was superior to traditional immunosuppressive medications at helping people with ANCA-associated…
The combination antibiotic trimethoprim-sulfamethoxazole (TMP-SMX) may help prevent serious infections for people with granulomatosis with polyangiitis (GPA) who are taking…
Conduit Pharmaceuticals is planning to launch Phase 2a clinical trials to test its lead oral candidate AZD1656 in people…